| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Fischer, Marie, 1970-
(författare)
-
Mast cells in Hodgkin lymphoma : or 'What's a nice cell like you doing in a tumour like this?'
- 2004
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- Mast cell (MC) accumulation around tumours is an old observation gaining new relevance due to the multifaceted nature of MCs and their many roles in immunity, beyond allergy. Knowledge about tumour specific recruitment of, and interactions with, MCs is needed to unravel the function of their presence.This study investigates the participation of mast cells in the tumourigenesis of Hodgkin lymphoma (HL), a tumour with many inflammatory features. We report that MC recruitment into HL lymphomatous tissue is possibly due to the production of CCL5/RANTES by malignant Hodgkin and Reed-Sternberg (HRS) cells. In addition, increased levels of IL-9, a cytokine implicated in mast cell heterogeneity and as an autocrine growth factor for HRS cells, were found in HL patient sera and correlate with negative prognostic factors. The ubiquitous expression of CD30 by HRS cells has been implicated in HL tumour development. In HL tissue MCs were found to be the predominant CD30 ligand (CD30L) expressing cells, and through CD30L/CD30 engagement they induced a proliferative response in HRS cells. This interaction proved to be bi-directional as it induced a degranulation-independent de novo synthesis of a specific set of chemokines in MCs, including IL-8. This novel trigger of MC activation is suggested to be of importance also in atopic dermatitis (AD) and psoriasis since increased numbers of CD30L and IL-8 positive MCs were detected along with increased expression of CD30.Data presented in this study supports a specific recruitment of MCs into HL tumours and co-operative interactions between HRS cells and MCs. Our identification of reversed signalling via CD30L as a novel MC trigger provides a mechanism behind leukocyte infiltration and chronic development in diseases associated with CD30 and MCs, such as HL, AD and psoriasis.
|
|
| 5. |
- Levin Jakobsen, Anne-Marie, 1955, et al.
(författare)
-
NESP55, a novel chromogranin-like peptide, is expressed in endocrine tumours of the pancreas and adrenal medulla but not in ileal carcinoids.
- 2003
-
Ingår i: British journal of cancer. - : Springer Science and Business Media LLC. - 0007-0920 .- 1532-1827. ; 88:11, s. 1746-54
-
Tidskriftsartikel (refereegranskat)abstract
- Neuroendocrine secretory protein 55, NESP55, is an acidic protein belonging to the chromogranin family. The distribution of NESP55 in human tumours is not known. The aim of the present study was to study the expression of NESP55 in human gastrointestinal, pancreatic and adrenal tumours. A total of 118 human endocrine and nonendocrine tumours were examined by immunocytochemistry, and compared to the expression of chromogranin A (CgA) in the same tumours. Pancreatic endocrine tumours (14 out of 25), pheochromocytomas (19 out of 19), and neuroblastomas (seven out of 14) expressed NESP55, with the same strong labelling pattern in both benign and malignant tumours. Expression of NESP55 in pancreatic endocrine tumours and pheochromocytomas was confirmed by Western and Northern blot analysis. Immunocytochemical analysis demonstrated no labelling in ileal carcinoids (zero out of 15), and adrenocortical adenomas (zero out of 15). The majority of gastrointestinal and pancreatic carcinomas were negative for NESP55, with focal staining observed in two out of 30 tumours. In contrast, CgA was present in all neuroendocrine tumours examined (25 out of 25 pancreatic endocrine tumours, 19 out of 19 pheochromocytomas, 14 out of 14 neuroblastomas and 15 out of 15 ileal carcinoids). Thus, the expression of NESP55 in endocrine tumours of the gastrointestinal tract, pancreas and adrenals differs from that of CgA. Neuroendocrine secretory protein 55 is found in a subset of neuroendocrine tumours showing differentiation towards adrenal chromaffin cells and pancreatic islets cells.
|
|
| 6. |
|
|
| 7. |
- Molin, Daniel, et al.
(författare)
-
Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease
- 2001
-
Ingår i: British Journal of Haematology. - : Wiley. - 0007-1048 .- 1365-2141. ; 114:3, s. 616-623
-
Tidskriftsartikel (refereegranskat)abstract
- Hodgkin's disease (HD) tumours are characterized by the presence of few tumour cells, the Hodgkin and Reed-Sternberg (HRS) cells, surrounded by a large amount of non-neoplastic cells. The role of this cell infiltrate for the development of HD is not known. CD30, belonging to the tumour necrosis factor receptor superfamily, is highly expressed on HRS cells and believed to be involved in tumourigenesis and tumour progression. Tumour samples from 42 patients were immunohistochemically double-stained for tryptase, a mast cell-specific proteinase and CD30 ligand (CD30L). Tryptase-positive mast cells were present in all tumours. Of these cells, 50% expressed CD30L and 66% of the CD30L-positive cells were mast cells. CD30L mRNA in in vitro developed normal mast cells and malignant human and murine mast cell lines was detected using reverse transcription polymerase chain reaction. CD30L protein expressed on human mast cells was detected using flow cytometry. In a co-culture assay, the human mast cell line HMC-1 stimulated thymidine uptake in HRS cell lines, and the stimulation could be blocked using CD30L-specific monoclonal antibodies. In conclusion, mast cells are present in HD tumours and are the predominant CD30L-expressing cells. CD30L-CD30 interaction is a pathway by which mast cells may stimulate DNA synthesis in HRS cells.
|
|
| 8. |
- Walther, Bernhard, et al.
(författare)
-
Flow processing and gel formation : A promising combination for the design of the shape of gelatin drops
- 2002
-
Ingår i: Food Hydrocolloids. - 0268-005X .- 1873-7137. ; 16:6, s. 633-643
-
Tidskriftsartikel (refereegranskat)abstract
- This investigation is a model study on how drops can be structured by a combination of flow processing and gel formation. Different drop shapes were created by subjecting gelatin drops to various flow conditions. At the same time, temperature induced gel formation of the drops fixed the shape. Elongated drops and drops of complex form were created. The flow to shape the gelatin drops was generated in a 4-Roll Mill (4RM) and silicon oil was used as the continuous phase. During processing in the 4RM, the drops were allowed to follow two different streamlines and thereby being subjected to purely elongational and a mixture of shear and elongational flow. The drop size varied between 1.5 and 2.8 mm. The gelatin drops were temperature conditioned before the experiment to 60 °C and the silicon oil to 5 °C. The drops were cooled via the cold oil phase during the flow process, and gel formation was induced. A gel strength strong enough to resist further deformation was achieved at different fixation zones in the 4RM, and this depended on the process parameters of flow type, flow rate, drop size and gelatin concentration. The shape created was directly related to the fixation zone. There was a broad freedom to combine different parameter values to fix a drop in a certain fixation zone. The mechanism behind the various drop shapes is explained in terms of elongation, relaxation, pinching and gel formation in relation to flow pattern and time in the 4RM. Elongation is a major contribution to the mechanism in the case of elongated shapes, while elongation followed by relaxation and pinching are the dominant determinants in the creation of complex shapes. © 2002 Elsevier Science Ltd. All rights reserved.
|
|
| 9. |
|
|
